Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
CEO: Bernard J. Zovighian. Company website
Edwards Lifesciences Corporation (EW) trades at $88.26, up 0.01% on the day, as of Sep 20, 2026 14:59 UTC.
Edwards Lifesciences Corporation has a market capitalisation of $50.82B, calculated from the live EW share price and shares outstanding.
EW trades at a trailing P/E of 50.72, from earnings per share of $1.74 over the last twelve months.
Edwards Lifesciences Corporation generated revenue of $6.51B over the trailing twelve months, which puts the stock at 7.80 times sales.
EW has traded between $72.30 and $96.29 over the past 52 weeks, and the last price is 8.3% below that high.
Yes. Edwards Lifesciences Corporation keeps 15.43% of revenue as net income over the trailing twelve months.
Wall Street analysts rate EW Buy, with an average price target of $101.70, 15.2% above the current price.
Edwards Lifesciences Corporation is classified under the Healthcare sector and the Medical - Devices industry, and is domiciled in US.
Bernard J. Zovighian is the chief executive of Edwards Lifesciences Corporation, which employs 16,000 people.
QFI Terminal shows EW with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open EW in Terminal See plans